Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579061 | 0.86 | L3MBTL1 (0.44) | LMNAPPARGHDAC2PTPRCPTPN13 | |
| SCHEMBL3579064 | 0.86 | L3MBTL1 (0.44) | LMNAPPARGHDAC2PTPRCPTPN13 | |
| SCHEMBL3580528 | 0.86 | L3MBTL1 (0.44) | LMNAPPARGHDAC2PTPRCPTPN13 | |
| SCHEMBL15027682 | 0.84 | PPARG (0.42) | LMNAPPARGHDAC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL13345392 | 0.84 | HTT (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5079142 | 0.80 | LTB4R (0.47) | LMNAPPARGHDAC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL26100458 | 0.80 | LMNA (0.42) | LMNAALDH1A1SMN1; SMN2TBXAS1LTB4R | |
| SCHEMBL3578759 | 0.80 | ATM (0.40) | PPARGHDAC2PPARA | |
| SCHEMBL3578761 | 0.80 | ATM (0.40) | PPARGHDAC2PPARA | |
| SCHEMBL15027984 | 0.77 | ALOX5 (0.39) | PPARGALDH1A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | LMNA 3032/4885PPARG 1330/4885HDAC2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.